Drugs / TAF
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05861674 Background | Jun 2023 → Jul 2024 | hepatitis D virus infection | Huahui Health | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05861674 ↗ |
| Route | Oral | “TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period” NCT05861674 ↗ |